Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Deciphera Pharmaceuticals (DCPH) Tops Q2 EPS by 17c
August 4, 2020 4:59 PM EDTDeciphera Pharmaceuticals (NASDAQ: DCPH) reported Q2 EPS of ($1.20), $0.17 better than the analyst estimate of ($1.37). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $890 thousand.
The second quarter for Deciphera was a transformational one as we launched our first commercial... More
